Disseminated histoplasmosis in the Americas – a lethal blind spot of health organisations
January 08 2016
The global health tragedy that is avoidable deaths from histoplasmosis, has been highlighted in the current edition of the Journal AIDS (AIDS 2016, 30:167–170). Despite a burden of ~1,600,000 HIV patients in South and Central America, most hospitals have no access to rapid diagnostic techniques and often lack the right treatment. Histoplasma capsulatum is endemic and common in the Americas. The lack of a rapid and affordable test that is sensitive, specific, equipment free and easy to use compounds the tragedy. The systematic failure to diagnose this lethal infection means clinicians cannot stop their patients dying, nor truly estimate the actual burden of this disease. So public and international health authorities appear to have a “blind spot” for histoplasmosis.
In some areas eg. Panama – a study showed 7.65% of HIV positive patients had Histoplasma capsulatum determined by culturing, rising to as high as 43% in other countries like Brazil. In French Guiana 85% of HIV patients in hospital with CD4+ less than 50 had disseminated histoplasmosis. In Guatemala, histoplasmosis is the second commonest infection after tuberculosis but with a higher mortality. In other centres, histoplasmosis is more common than tuberculosis (TB). Many cases are only diagnosed after death. The historical death rate is 40%, if treated, but 100% if not, and relapse is also common, after an apparent ‘cure’. Patient with histoplasmosis
A recent rise to 60% of ‘culture negative TB’ in AIDS patients may be linked to the possible misdiagnosis of histoplasmosis as TB. Culture negative TB patients have a higher mortality than culture positive cases.
It is easy to confuse a diagnosis of histoplasmosis in the early stages - but disseminated histoplasmosis presents with more diarrhoea, abdominal pain, hepatosplenomegaly, marked leucopenia and sometimes skin lesions than TB, and has fewer respiratory features - less cough, less breathlessness, no haemoptysis and fewer abnormalities on the chest Xray. (See Gutierrez et al. 2005)
This news item was written from an Editorial Opinion in AIDS 2016, 30:167–170
(The authors were Mathieu Nachera, Antoine Adenis, Eduardo Arathoon, Blanca Samayoa, Dalia Lau-Bonilla, Beatriz L. Gomez, Angela Tobon, Diego Caceresd, Silvia Marques da Silva, Maurimelia Mesquita da Costa, Rosely Zancope, Terezinha Silva Leita ̃o, Margarete Do Socorro Mendonca Gomes, Ivina Lopes Lima, Rosilene Malcher Leite, Stephen Vreden, Marja Van Eer, Sigrid Mac Donald, Sandra Hermelin, Magalie Demar, Denis Blanchet, Felix Djossou, Vincent Vantilcke, Maria Mercedez Panizo, Maribel Dolande,Christina Canteros, Marcus Lacerda, Pierre Couppie ́ , Angela Restrepo.